Stephen Stamp joins board at Eusa Pharma

pharmafile | September 7, 2010 | Appointment | Sales and Marketing Eusa Pharma, appointment, sales and marketing 

Transatlantic specialty company Eusa Pharma has appointed Stephen Stamp to its board as an independent non-executive director.

Stephen has previously held board-level roles at Xanodyne Pharmaceuticals and Shire Pharmaceuticals, and was most recently chief financial officer at K-V Pharmaceutical Company.

Commenting on his appointment, Stephen said, “Having witnessed EUSA’s impressive growth, I am excited to be helping the company achieve its ambitious plans.

“Having already built a robust commercial infrastructure in the US and Europe, and a wider global distribution network, I believe EUSA is well placed for future success, and I welcome the opportunity to be part of the company’s continued rapid development.”

Eusa is jointly based in Oxford, UK and Langhorne, PA, in the US and focuses on in-licensing, developing and marketing late-stage oncology, pain control and critical care products.

Related Content

shutterstock_38078521

EUSA Pharma gets FDA green light to evaluate IL-6 inhibitor siltuximab in COVID-19 patients

Efforts push on to discover an effective treatment for COVID-19 in more than 100 different …

eusa

EUSA Pharma’s COVID-19 drug improves or stabilises respiratory condition in 76% of patients

EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the …

shutterstock_212432119

EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications

Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the …

Latest content